The impact of prophyactic treatment on children with severe haemophilia.
about
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.Prophylaxis in developed and in emerging countries.Evaluation of outcome of care in patients with haemophilia.Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.The overall effectiveness of prophylaxis in severe haemophilia.Prophylactic therapy for haemophilia: early experience.When to start and when to stop primary prophylaxis in patients with severe haemophilia.Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Home management of haemophilia.Central venous access devices in haemophilia.Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?Quality of life assessment in haemophilia.Treatment of hemophilia: a review of current advances and ongoing issuesThe effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophiliaOptimizing factor prophylaxis for the haemophilia population: where do we stand?Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study.Optimizing outcomes for patients with severe haemophilia A.Can early subclinical gait changes in children with haemophilia be identified using the GAITRite walkway.Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.Secondary prophylaxis in adolescent and adult haemophiliacs.Self-management and skills acquisition in boys with haemophilia.Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.Novel drugs to treat hemophilia.Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management.Changing paradigm of prophylaxis with longer acting factor concentrates.Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.The impact of sport on health status, psychological well-being and physical performance of adults with haemophilia.Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.The Malmö-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts.Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.
P2860
Q24234413-E5FC994E-4BFE-446A-8A9C-2BCC7E8D1EB9Q30539596-C032F55F-5B45-47AD-AA93-A364464FC684Q33634745-DFA3D820-5076-43F6-A6E6-A2D90ED446FAQ33904447-ECC359ED-7493-4AB2-B188-3295F350C8D4Q34094037-F50F67E5-2F5F-473B-9D3F-B378F948D817Q34522059-CC957722-6CBD-46B4-8959-6664890C6AD6Q34636878-CA407BA1-5FC7-45B5-8CB0-BD798554857EQ34637116-DBBF917C-C90B-4E84-8EF6-E206BCEB3FA8Q35106858-83B77AD5-461E-4E56-ACCB-C61A9BD22C23Q35106860-4410F784-6F52-474F-B7E3-97BF576C7D2CQ35112428-6310C5E4-0595-471C-9AEE-9CD8EFC64ED6Q35112433-79261B6C-A14C-496B-8F78-7D3267EC0E32Q35112459-93E79E1E-BE0D-4311-A008-BCA64AB9D58CQ35565320-5DC1CF4D-D20F-4200-9AF2-02023DF04843Q35666730-0EA4B5A3-D76F-4B14-B464-9465F6A2818FQ35666735-5B8B9CA1-3B70-4A1E-828B-4645AD9BBEE1Q35666740-228D9173-E81E-4324-97FF-7D3FA42EC5ECQ35677000-8963A368-C96A-4E0C-8ADD-8D2DAC6ADDD9Q35683781-C0E0E4F2-9DCE-4F47-BBD3-D11F91FD5CEEQ35826358-20114170-5977-4260-91BD-85BD67AB6997Q35915686-91DCED13-CABD-4F5B-AD41-5FF8CC73E75DQ35932549-83403AF2-9441-401C-9E6A-7127384E6006Q36473108-525D0EC4-7E1F-4DF3-BC7F-3EF4B270CDB9Q36687522-429EF917-E64B-4F6C-8967-8B07DFCF947FQ36703072-E20AFA7B-0247-49F6-95CC-D250677A774AQ36932769-3F9CB23A-4E96-453B-BC8F-20F23D9146EFQ36945950-CE4B7118-8C5C-4659-B072-DEB8AD9BAC68Q37052161-FC63E39F-094C-4A11-9E5A-20BB8B322D50Q37119647-C32E5723-F544-43BD-9082-58F3278033DBQ37333464-BF4B77F5-EDCF-412C-AB89-BF4D8860A8C6Q37619008-FFD6C070-1181-4466-8289-DC8FA2086220Q37775029-EC65A44F-01D2-49FF-9768-E4C80AC85265Q37952373-A6ACC0A9-FDA8-4778-B9E6-9ABC0E95F428Q38206858-D5E1DDD2-1B6E-47A8-9330-0D51FF8527BEQ38731189-8A8B526F-3E67-4ADC-A4C4-F37726EF3004Q39741938-997EC2E7-231E-4620-8709-E0C305396555Q39952685-DAF4E344-1A49-4C65-8846-6319461F3BF8Q40654703-B34ADD6A-8E8C-4186-9B1E-D1166E18F92AQ40830130-BB8BA314-E600-41A9-BC7C-E9615F3BBD36Q41483187-87317BC9-E184-41D1-8CD7-C8A46AFB8AAD
P2860
The impact of prophyactic treatment on children with severe haemophilia.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
The impact of prophyactic treatment on children with severe haemophilia.
@en
The impact of prophyactic treatment on children with severe haemophilia.
@nl
type
label
The impact of prophyactic treatment on children with severe haemophilia.
@en
The impact of prophyactic treatment on children with severe haemophilia.
@nl
prefLabel
The impact of prophyactic treatment on children with severe haemophilia.
@en
The impact of prophyactic treatment on children with severe haemophilia.
@nl
P2093
P1476
The impact of prophyactic treatment on children with severe haemophilia.
@en
P2093
P304
P356
10.1046/J.1365-2141.1996.420960.X
P407
P577
1996-03-01T00:00:00Z